

Extension Seminar in Cardiology

Preliminary program

Self-paced learning package: available from Friday 2 May 2025

Topic	Presentations & presenter	Learning objectives
Valvular disease	Aortic Valve Disease Dr. Laura Selkrig , <i>Non-interventional Cardiologist, Latrobe Regional Hospital, Gippsland, Vic</i>	<ul style="list-style-type: none"> • Overview the anatomy and physiology of the aortic valve • Explain the symptoms related to a regurgitant valve and to a stenosed aortic valve. • Describe the implications of the gradient pressures and their impact on symptoms • Explain the medical therapy required for the patient with a stenosed aortic valve, including: <ul style="list-style-type: none"> ○ Ischaemia management ○ Atrial fibrillation management ○ Fluid management
	Mitral Valve Disease Dr. Laura Selkrig , <i>Non-interventional Cardiologist, Latrobe Regional Hospital, Gippsland, Vic</i>	<ul style="list-style-type: none"> • Overview the anatomy and physiology of the mitral valve and the structural apparatus attached • Explain the causes of a regurgitant mitral valve and the implications for the patient • Describe the surgical corrections available for mitral valve disease and the implications for the patient and the medications required, including: <ul style="list-style-type: none"> ○ Anticoagulation ○ Heart failure therapies
	TAVI Dr. Michael Mok , <i>Interventional Cardiologist, University Hospital Geelong, Geelong, Vic</i>	<ul style="list-style-type: none"> • Describe the investigations involved in assessing patients suitability for TAVI • Describe the risks of brady-arrhythmias post TAVI and the need for pacemakers • Describe the anti-thrombotic requirements for a patient receiving a TAVI
Aortic stenosis	Self-directed case study Garth Birdsey , <i>Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic</i>	<ul style="list-style-type: none"> • Explain the ward management of a patient with aortic stenosis • Describe the therapies involved in this management, including how to titrate each of them to effect

<p>Infiltrative cardio-myopathies</p>	<p>Amyloidosis diagnostics & pharmacological therapy</p> <p>Dr. Satish Ramkumar, <i>Consultant Cardiologist; Director of Physician Education, Victorian Heart Hospital, Monash Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> • Differentiate between the two forms of cardiac amyloidosis • Identify signs and symptoms of cardiac amyloidosis • Describe the diagnostics involved in cardiac amyloidosis <ul style="list-style-type: none"> ○ Bone scan ○ Echocardiography ○ Cardiac MRI ○ Biopsy • Explain the pharmacological therapy (mechanism, impact on symptoms and survival) for transthyretin amyloidosis, including: <ul style="list-style-type: none"> ○ Managing the HFpEF symptoms ○ Pitfalls of using ACE inhibitors, ARB's and sacubitril. ○ Tafamidis • Explain how to manage decline in renal function in these patients
<p>Hypertrophic Cardio-myopathies</p>	<p>Genetics & Diagnostics</p> <p>Dr Andris Ellims, <i>Director, HCM Clinic, Alfred Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> • Describe the diagnostics involved in hypertrophic cardiomyopathies: <ul style="list-style-type: none"> ○ Echocardiography ○ Cardiac MRI ○ Family history ○ Genetics of the condition • Outline the symptoms the patient will describe • Explain the management of arrhythmia in this patient group: <ul style="list-style-type: none"> ○ Amiodarone use plus or minus betablockade ○ Use of Implantable defibrillators • Describe the surgical and invasive treatment options available: • Intracoronary alcohol • Surgical debulking • Explain the use of targeted pharmacological treatment: <ul style="list-style-type: none"> ○ Disopyramide ○ Verapamil ○ Mavacamten dosing • Explain the role of echocardiogram monitoring for dose adjustment • Overview the management of associated drug interactions • Identify emerging therapies for treatment and management

Extension Seminar in Cardiology

Preliminary Program

Live virtual seminar: Saturday 14 June 2025

All times are listed in AEST. The below may be subject to change

Time (AEST)	Session & presenter
0945-1000	Online login and registration available
1000-1030	Welcome, housekeeping, & review of online learning content Garth Birdsey , Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic
1030-1115	Presentation: Surgical management of heart valve disease Michael Byrom , Cardiothoracic Surgeon, University Hospital Geelong, Geelong, Vic
1115-1130	Break
1130-1200	Case session: Aortic Stenosis case: Questions & discussion Garth Birdsey , Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic
1200-1230	Break
1230-1330	Case presentation: Cardiac Amyloidosis Anna Truong , Clinical Cardiology Pharmacist, Victorian Heart Hospital, Monash Health, Melbourne, Vic
1330-1345	Break
1345-1430	Case study: Hypertrophic cardiomyopathies Tory Warner , Lead Clinical Pharmacist Cardiology, Alfred Health, Melbourne, Vic
1430-1515	Q&A Garth Birdsey , Senior Clinician Pharmacist, Departments of Pharmacy and Cardiac Services, Barwon Health, Geelong, Vic
1515	Seminar close

Please note presentation recordings will not be available from the live day seminar.